BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 10:08:14 2024-05-24 am EDT			5-day change	1st Jan Change
0.576 ^EUR	-4.00%		+0.70%	-46.67%

May. 15	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI
May. 02	Benevolentai S.A. Announces Directorate Changes	CI

BenevolentAI : Benevolent AI, - Result of Annual General Meeting

May 02, 2024 at 11:36 am EDT

Benevolent AI

Benevolent AI

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date02 may 2024 - 15:12

Statutory nameBenevolent AI

TitleResult of Annual General Meeting

Previous result

Next result

Date last update: 02 May 2024

Attachments

Original Link
Permalink

Disclaimer

BenevolentAi SA published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 15:35:01 UTC.

Latest news about BenevolentAI

BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	May. 15	CI
Benevolentai S.A. Announces Directorate Changes	May. 02	CI
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	Apr. 15	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
Kenneth Mulvany Sends a Letter to Benovelent AI	Apr. 02	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	Mar. 25	CI
BenevolentAI Announces Executive Changes	Mar. 20	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member	Jan. 24	CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer	Jan. 24	CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO	Jan. 22	AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	23-09-26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
BenevolentAI S.A. Announces Executive Changes	23-09-21	CI
BenevolentAI S.A. Announces Management Changes	23-09-21	CI
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery	23-09-20	DJ
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	23-09-20	MT
BenevolentAI Signs Strategic Collaboration with Merck	23-09-20	CI
BenevolentAI Appoints Chief Revenue Officer	23-09-18	MT
BenevolentAI Appoints Catherine Isted as Chief Financial Officer	23-09-11	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	23-08-31	CI
BenevolentAI Announces Retirement of Jackie Hunter as Non-Executive Director	23-06-21	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	23-06-05	CI

Chart BenevolentAI

Duration

Period

More charts

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Sector

Biotechnology & Medical Research

Calendar

2024-09-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5109 GBP

Average target price

1.935 GBP

Spread / Average Target

+278.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-46.67%	79.19M
MODERNA, INC.	+69.84%	62.86B
IQVIA HOLDINGS INC.	-1.03%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.54%	12.67B
UNITED THERAPEUTICS CORPORATION	+23.99%	12.27B
MEDPACE HOLDINGS, INC.	+28.41%	12.07B

Other Biotechnology & Medical Research